/Oxford vaccine progressing very well, 10,000 more to be inoculated – Business Insider
10,000 more to be inoculated

Oxford vaccine progressing very well, 10,000 more to be inoculated – Business Insider


 

Oxford vaccine

progressing very well,

10,000 more to be inoculated

 

  • The head of the Oxford Vaccine Group said Friday that clinic trials on its vaccine for the coronavirus are “progressing very well.”
  • 1,000 people have already been inoculated. The next stage will see 10,000 more given the treatment through May and June, Andrew Pollard said.
  • The trial vaccine is called as AZD1222 or ChAdOx1 nCoV-19. It was first tested on humans on April 23, following success in macaque monkeys.
  • The group said they hoped for clinical test results in two months, but that it could take as long as six.
  • Visit Business Insider’s homepage for more stories.

The head of the Oxford Vaccine Group said Friday that its clinical trials are “progressing very well” and that the program will inoculate 10,000 new people.

“We are now initiating studies to evaluate how well the vaccine induces immune responses in older adults,” Professor Andrew Pollard, head of the Oxford Vaccine Group, said in a press release.

‘The clinical studies are progressing very well.”

The trial vaccine is called AZD1222 or ChAdOx1 nCoV-19. It was first tested on two humans on April 23 in Oxford, following promising results on six macaque monkeys in the US in March.

1,000 people have since been given the trial vaccine across the UK, but children and those over 55 were excluded.

10,260 new people, including the elderly, will be given the trial vaccine in May and June, the group said. Subjects keep a diary and submit regular blood samples.

inoculated
Oxford vaccine progressing very well, 10,000 more to be inoculated

 

The first human trial of the ChAdOx1 nCoV-19. vaccine from the Oxford Vaccine Group.

YouTube/University of Oxford

The group said that results would be available “in a couple of months,” but that “it could take up to six months” depending on outside factors.

Progress could be slowed if the UK coronavirus outbreak slows down, because it means fewer test subjects will be exposed naturally to the virus.

To mitigate this potential issue, the group is prioritizing volunteers with “a higher chance of being exposed,” like frontline healthcare workers.

The Oxford Vaccine Group is one of a few elite laboratories and facilities leading the race to find a vaccine.

Oxford vaccine progressing
pharmaceutical

 

A sign outside of the University of Oxford Old Road Campus, where a coronavirus vaccine is developed by the University of Oxford, England on April 29, 2020.

Getty

On Monday, the US-based firm Moderna tentatively said that all 45 people given its trial vaccine had created immune responses that could help protect them from the coronavirus.

Dr Anthony Fauci, the director of the National Institute on Allergy and Infectious Disease said he was “cautiously optimistic about it.”

The drugs giant Pfizer, who are partnered with BioNTech, began trialling its BNT162 vaccine on humans on May 5. It is yet to announce preliminary results.

A scientist checks quality control of vaccine vials for correct volume at the Clinical Biomanufacturing Facility (CBF) in Oxford, Britain, April 2, 2020. Picture taken April 2, 2020. Sean Elias/Handout via REUTERS THIS IMAGE HAS BEEN SUPPLIED BY A THIRD PARTY. MANDATORY CREDIT. NO RESALES. NO ARCHIVES

 

A scientist checks vaccine vials for correct volume at the Clinical Biomanufacturing Facility (CBF) in Oxford, UK, on April 2, 2020.

Sean Elias/Handout via REUTERS

In total, 12 vaccines in development around the world are in the human trial stage, according to The Associated Press.

Sarah Gilbert, a professor of vaccinology working on the Oxford vaccine said on April 11 that the earliest it could be ready was September, but that such a date was very optimistic.

Whether the vaccine is approved or not, it is already in high demand.

pharmaceutical
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid

 

The AstraZeneca building in Luton, Britain.

Getty

The Oxford Vaccine Group is partnered with pharmaceuticals giant AstraZeneca, and on Thursday, the US government agreed to pay up to $1.2 billion for 300 million doses of the vaccine

Last month, the world’s largest vaccine maker by doses, The Serum Institute of India, said it too would manufacture 40 million doses, without yet knowing whether it works.

“The decision — at our own risk and cost — has been solely taken to get a jump-start on manufacturing,” CEO Adar Poonawalla said.

Despite the progress, there are concerns that even when a vaccine becomes available, a global rollout will be hampered by a shortage of the glass vials and lids necessary to distribute the product.

Something is loading.

Original Source